

## ANSWERING REVIEWERS



February 18<sup>th</sup>, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: ESPS Manuscript NO 6877).

**Title:** Clinical management of advanced gastric cancer: the role of new molecular drugs

**Author:** Ferdinando De Vita, Natale Di Martino, Alessio Fabozzi, Maria Maddalena Laterza, Jole Ventriglia, Beatrice Savastano, Angelica Petrillo, Valentina Gambardella, Vincenzo Sforza, Luigi Marano, Annamaria Auricchio, Gennaro Galiza, Fortunato Ciardiello, Michele Orditura

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 6877

The manuscript has been improved according to the suggestions of reviewers (changes are written in red in the text):

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

- (1) Page 10 line 10: ORR changed in "overall response rate (ORR)"
- (2) Page 14 line 31: EC changed in "esophageal cancer (EC)"
- (3) Page 18 line 26: MST changed in "median survival time"
- (4) Page 21 line 3: FISH changed in "fluorescence in situ hybridization (FISH)"
- (5) Page 21 line 16: ISH changed in "FISH"
- (6) Page 26 line 22: PK changed in "pharmacokinetics (PK)"
- (7) Page 29 line 3: MMC changed in "mitomycin C (MMC)"
- (8) Table 1: line 1 column 5: N changed in "number"
- (9) Table 1: added in footnotes: O: oxaliplatin - TXT: docetaxel - BSC: best supportive care - RR: response rate - OS: overall survival - TTP/PFS: time to progression/progression free survival
- (10) Table 2.1: line 1 column 5: N changed in "number"
- (11) Table 2.1: added in footnotes: RR: response rate - OS: overall survival - TTP: time to progression - GEJ: gastro-esophageal junction
- (12) Table 2.2: line 1 column 5: N changed in "number"
- (13) Table 2.2: added in footnotes: FOLFIRI: 5fluorouracil plus folinic acid plus irinotecan - FUFOX: 5fluorouracil plus oxaliplatin - DOCOX: docetaxel plus oxaliplatin - XELOX: capecitabine plus oxaliplatin - RR: response rate - OS: overall survival - TTP: time to progression
- (14) Table 3: line 1 column 5: N changed in "number"
- (15) Table 3: added in footnotes: OS: overall survival - TTP/PFS: time to progression/progression free survival
- (16) Table 4: line 1 column 5: N changed in "number"
- (17) Table 4: added in footnotes: OS: overall survival - PFS: progression free survival
- (18) Rearrangement of all authors affiliation according to journal guidelines

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Ferdinando De Vita

Dr. Ferdinando De Vita, MD, PhD – ID (00907364)

Assistant Professor of Oncology

Second University of Naples School of Medicine

F. Magrassi – A. Lanzara”. Department of Clinical and Experimental Medicine and Surgery

c/o II Policlinico, Edificio 3, Via Pansini, 5 80131 Naples, Italy

Tel: +39-081-566-6713 Fax: +39-081-566-6732

e-mail: [ferdinando.devita@unina2.it](mailto:ferdinando.devita@unina2.it) – [fernandodevita@yahoo.it](mailto:fernandodevita@yahoo.it)